Overview
- The executive order, signed Saturday, directs the FDA to ease researcher access to LSD, psilocybin and ibogaine and to work with the DEA on special permits.
- About $50 million from existing Health Department budgets will support states that build tightly controlled treatment programs.
- The measure tells the Attorney General and Health and Human Services to quickly review rescheduling once a psychedelic completes successful Phase 3 trials to enable medical use.
- Trump framed the move as a response to severe, treatment‑resistant illness and highlighted needs of veterans with PTSD and high suicide rates.
- The action does not change current federal schedules, so broad clinical use remains limited for now, and safety concerns remain, including known heart risks with ibogaine.